Finland· FI-REL-REL63922
Vyloy
A zolbetuximab product containing zolbetuximab, registered in Finland by Astellas Pharma Europe B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Zolbetuximab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX31 (zolbetuximab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Zolbetuximab · ATC L01FX31
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Zolbetuximab
- Manufacturer
- Astellas Pharma Europe B.V.
- Country
- Finland (FI)
- ATC code
- L01FX31
- ATC class
- Zolbetuximab
- Defined daily dose
- 51.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Zolbetuximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVyloy 300 mgAstellas Pharma Europe
- SwitzerlandVyloy 300 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAstellas Pharma AG
- CzechiaVYLOYAstellas Pharma Europe B.V., Leiden
- SpainVYLOY 300 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAstellas Pharma Europe B.V.
- United KingdomVyloy 300mg powder for concentrate for solution for infusion vialsAstellas Pharma Ltd
- NorwayVyloyAstellas Pharma Europe B.V
- PolandVyloyAstellas Pharma Europe B.V.
- SwedenVyloy 300 mg Pulver till koncentrat till infusionsvätska, lösningAstellas Pharma Europe BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyloy
- Liechtenstein · Vyloy
- Norway · Vyloy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/29caf674-c625-4162-a974-a0e038a1d411 GET /v1/drugs/29caf674-c625-4162-a974-a0e038a1d411?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "300 mg",
"atc_label": "tsolbetuksimabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1856/003",
"fimea_rel_id": "REL63922",
"authorised_at": "2025-02-13"
}See everything about zolbetuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.